Refine by
Needle Free Articles & Analysis
34 news found
About Portal Instruments Portal Instruments is developing and commercializing a highly innovative needle-free drug delivery platform technology to transform the administration of medicines and improve the patient experience for chronic diseases. Portal’s needle-free delivery technology is derived from research at MIT and ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. ...
However, a sublingual vaccine can be stored at room temperature; therefore, they can resolve vaccine inequities by reducing distribution costs and improving vaccine accessibility in low- and middle-income countries (LMICs). Furthermore, such needle-free vaccines can improve immunization, especially in LMICs where there are not enough healthcare professionals and ...
The HD-MAP is Vaxxas’ proprietary vaccine patch technology, representing a possible alternative to traditional vaccine delivery methods which haven’t seen new technology beyond needle and syringe in over 170 years. In a matter of seconds, the HD-MAP delivers a small volume of vaccine just under the surface of skin where high amounts of immune cells are found. Being ...
Portal develops technology which allows for needle-free and high-speed subcutaneous injection of medicine and – via connectivity –adherence monitoring along the treatment journey by patient and medical care provider. ...
This makes it possible for other clinic staff, such as nursing assistants and registered nurses, to close wounds, which frees up time for dermatologists to handle more specialized or complex procedures. ...
ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats. This new study will build on Enesi’s successful Biomedical Advanced Research and Development Authority (BARDA) Drive Beyond the ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. Ms. Eagling-Vose brings over 20 years’ ...
Portal Instruments is developing a drug delivery platform that is needle-free, fast, and connected to redefine the patient experience. For patients who dread taking shots, Portal’s needle-free injector could offer a new alternative. Drug administration is over in half a second, making Portal’s ...
The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2 challenge compared to reported efficacy in NHP models of currently authorized vaccines. ...
The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination. Despite the substantial health and economic burden caused by RSV-associated illness, no vaccine is available. ...
Meissa is developing MV-012-968 as a needle-free, adjuvant-free vaccine to protect infants and at-risk, older adults from respiratory syncytial virus (RSV). ...
² The thing that these injection methods have in common is obviously the use of a needle, and a lot of people have an aversion to needles. Personally, I am not afraid of needles, but still the idea of stabbing myself once a week is pretty offputting. Besides that, having needles in the home can be unsettling if there are ...
The Article ‘A Total Meltdown‘ highlights how next generation vaccination technologies such as ImplaVax® needle-free, thermally stable unit solid dose vaccination platform could make a material impact on the ease of future deployment and reduce or eliminate the burden of cold chain ...
The results showed that a novel solid-dose ImplaVax® formulation of a recombinant E2 antigen CSF virus vaccine delivered subcutaneously using the ImplaVax® needle-free injection device generated a stronger immune response than standard liquid CSF vaccine formulations, particularly in terms of CSF virus-specific T-cell responses. ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained ...
Innovative needle-free injectable unit solid-dose presentation of recombinant H7N9 pandemic flu vaccine, created using Enesi’s ImplaVax technology, generated immune responses comparable with liquid vaccine and demonstrated excellent thermal stability at temperatures up to 40°C for six months. ...
Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces that its CEO, David Hipkiss will give a presentation at the upcoming World Vaccine Congress 2021 Virtual meeting (4-6 May 2021), which this year is ...
Moffitt Cancer Center has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care. In its continuing efforts of being at the ...
MV-014-212 offers significant potential advantages for COVID-19 vaccine global deployment, including needle-free intranasal administration, a single adjuvant-free dose to induce mucosal and systemic immunity, as well as a straightforward, economical, and scalable manufacturing process. ...